Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic
cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood …

Acute Myeloid Leukemia | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …

This study investigated the efficacy and safety of azacitidine maintenance in the
posttransplant setting based on the encouraging phase 1/2 reports for azacitidine …

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of
continuing chemotherapy or transplantation using either autologous or allogeneic stem …

Evidence suggest that even patients aged 70 or above benefit from specific AML therapy.
The fundamental decision in AML then becomes whether to recommend standard or …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Extramedullary (EM) manifestations of acute leukemia include a wide variety of clinically
significant phenomena that often pose therapeutic dilemmas. Myeloid sarcoma (MS) and …